HTA

NICE numbers at 20: trends in deals

https://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-trends-in-deals/

NICE numbers at 20 – a closer look at cancer

https://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-a-closer-look-at-cancer/

Who could replace Sir Andrew Dillon at NICE?

https://pharmaphorum.com/views-and-analysis/who-could-replace-sir-andrew-dillon-at-nice/

NICE’s track record in cancer drugs: the impact of the CDF and interim funding

https://pharmaphorum.com/views-and-analysis/nices-track-record-in-cancer-drugs-the-impact-of-the-cdf-and-interim-funding/

NICE numbers at 20

https://pharmaphorum.com/views-analysis-market-access/nice-numbers-20/

The shadow of Brexit on speed of access

https://pharmaphorum.com/views-analysis-market-access/the-shadow-of-brexit-on-speed-of-access/

Access to new medicines in Scotland: a perennial issue

https://pharmaphorum.com/views-and-analysis/access-to-new-medicines-in-scotland-a-perennial-issue/

Mandatory or voluntary? A sticking point for European HTA

https://pharmaphorum.com/views-analysis-market-access/mandatory-or-voluntary-a-sticking-point-for-european-hta/

Only 4 Weeks Until Orphan Drugs & Rare Diseases 2018

https://pharmaphorum.com/partner-content/only-4-weeks-until-orphan-drugs-rare-diseases-2018/

1 2 3 4

Close in 10 seconds

Pharmaphorum.com

Search